Contineum Therapeutics (CTNM) Stock Coverage Update: Price Target Revised | CTNM Stock News

Author's Avatar
May 19, 2025

May 19, 2025 - In recent developments concerning Contineum Therapeutics (CTNM, Financial), Morgan Stanley has announced adjustments to its stock coverage. Senior analyst Jeffrey Hung maintained the company's current stock rating at "Overweight," reflecting continued analyst confidence in the company's market position.

However, there has been a notable change in the price target for CTNM. The price target has been revised downward from $25.00 to $20.00, a decrease of 20%. This adjustment aligns with prevailing market conditions and strategic considerations as analyzed by Morgan Stanley.

The news follows a broader trend of cautious optimism in the pharmaceutical sector, with analysts balancing robust growth prospects against evolving market dynamics. The revised price target for CTNM is set in USD, and it underscores Morgan Stanley's strategic outlook on Contineum Therapeutics.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.